2020
”The entire FluoGuide team is working hard to capture the enormous potential of the Company to help patients and benefit shareholders...
FluoGuide has previously communicated its anticipation of a clean outcome of these studies which has now been confirmed. FluoGuide...
27 May, 2020
FluoGuide presents today at Orphan Drugs
Today, 27 May at 11:10 (CEST), FluoGuide’s CEO Morten Albrechtsen presents the company and some of the recent developments...
18 May, 2020
Registration at the Danish Business Authority
Number of shares and share capital
The change of registration procedure for the 27,737 shares does not change the total number of...
18 May, 2020
FluoGuide A/S - Flagging message
FluoGuide A/S (“FluoGuide” or “the Company”) hereby announce that due to dilution in connection to the warrant...
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed...
”We are very pleased with our development and our shareholders’ interest in FluoGuide. The proceed from the warrants will...
Warrants TO 1 that has not been subscribed for shares by Thursday 7 May 2020 or sold by Tuesday 5 May 2020 will expire and are thereafter...
29 April, 2020
FluoGuide A/S interview by BioStock Live now available
To watch the interview and presentation, please follow link. (https://fluoguide.com/investor/calendar-events/) For more information...